These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6538444)

  • 1. Drug holidays alter onset of oral movements in rats following chronic haloperidol.
    Sant WW; Ellison G
    Biol Psychiatry; 1984 Jan; 19(1):95-9. PubMed ID: 6538444
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic melperone administration does not enhance oral movements in rats.
    Gunne LM; Johansson P
    Acta Psychiatr Scand Suppl; 1989; 352():48-50. PubMed ID: 2573241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
    Andreassen OA; Ferrante RJ; Aamo TO; Beal MF; Jørgensen HA
    Neuroscience; 2003; 122(3):717-25. PubMed ID: 14622915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior.
    Saldaña M; Bonastre M; Aguilar E; Marin C
    Exp Neurol; 2007 Feb; 203(2):302-8. PubMed ID: 17069804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for oral dyskinesia in rats.
    Gunne LM; Growdon JH
    J Clin Psychopharmacol; 1982 Oct; 2(5):308-11. PubMed ID: 6290544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
    Vamvakidès A
    Agressologie; 1986 Nov; 27(10):819-21. PubMed ID: 3812899
    [No Abstract]   [Full Text] [Related]  

  • 15. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral interactions induced by chronic neuroleptic therapy in persons with mental retardation.
    Schroeder SR; Gualtieri CT
    Psychopharmacol Bull; 1985; 21(2):310-5. PubMed ID: 2860695
    [No Abstract]   [Full Text] [Related]  

  • 17. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors.
    Pollock J; Kornetsky C
    Neuropsychopharmacology; 1991 Jun; 4(4):245-9. PubMed ID: 1678260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
    Gao XM; Kakigi T; Friedman MB; Tamminga CA
    J Neural Transm Gen Sect; 1994; 95(1):63-9. PubMed ID: 7857587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.
    Rupniak NM; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1985; 85(1):71-9. PubMed ID: 2858901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.